WebJan 24, 2024 · Statera Biopharma (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and... WebStatera BioPharma, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops novel second generation immune therapies to deliver immune …
Biotechnology (BK2069) Stock Price,News,Quote-Moomoo
WebFORT COLLINS, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Statera Biopharma (Nasdaq: STAB) (the “Company”), a biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced the Company received a letter from the Listing Qualifications Department of The Nasdaq … WebApr 12, 2024 · Most relevant news about STATERA BIOPHARMA, INC. 03/15: Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. CI. 01/17: Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI I.. CI. 01/11: Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Co.. CI. 2024: bobby tarantino 3 tracklist
15th Annual Medical Device Compliance Congress BioPharma Dive
WebJun 12, 2024 · From Stress Engineering Services, Inc. Bio-Rad’s QX600 Droplet Digital PCR System Advancing Measurable Residual Disease Research From Bio-Rad Hive-Zox … WebStatera Biopharma, Inc. (formerly Cytocom, Inc.) is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, … WebApr 10, 2024 · Subsequent to the merger, CBLI adopted a new corporate name, "Statera BioPharma, Inc.", with the ticker symbol "STAB," effective on September 1, 2024 ("Statera"). Statera emerged as a publicly traded entity following the merger with CBLI. ... More news: Financials (USD) Sales 2024---Net income 2024-3,54 M--Net Debt 2024: 0,55 M--P/E ratio … clint eastwood western preacher